Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Clinuvel, Retrophin deal

Clinuvel rejected an unsolicited July proposal from Retrophin to acquire Clinuvel in either a cash or stock deal. The cash deal values Clinuvel at A$92.2 million ($85.6 million) and the

Read the full 307 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE